Abstract
The presence of left ventricular hypertrophy in hypertensive patients has been linked with increased likelihood for developing congestive heart failure, the potential for myocardial ischemia and the inherent risk for sudden death. In this paper we review current knowledge regarding the role of left ventricular hypertrophy in cardiac morbidity and mortality and emphasize the need for further study to explore the efficacy of pharmaceutical agents in reducing cardiac complications of hypertension in high-risk patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
